FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. Versions of a human CD37 specific antibody are presented, each containing a variable site of a light and heavy chain. A coding nucleic acid and a based expression vector are described. There are disclosed: a host cell containing a vector, a method of producing the antibody with using the cell, and also a composition for decreasing the B-cell count and a method of treating diseases associated with aberrant B-cell activity, with using the CD37-specific antibodies.
EFFECT: use of the invention provides specific loss of 80% BJAB cells at the antibody concentration 10 mcg/ml, and also increases the survival rate of Daudi mice as compared with Rhithuximab therapy that can find application for treating various tumours.
39 cl, 39 dwg, 7 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| APPLICATION OF SINGLE DOSE OF CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2421242C2 |
| IMMUNOTHERAPEUTIC AGENT COMBINED WITH CD37, AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT | 2009 |
|
RU2531754C2 |
| SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION | 2007 |
|
RU2487888C2 |
| CD37-IMMUNOTHERAPEUTIC COMBINATION THERAPY AND USING IT | 2009 |
|
RU2526156C2 |
| CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | 2011 |
|
RU2742743C2 |
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| CHIMERIC THERAPEUTIC ANTI-CD-37 ANTIBODY HH1 | 2012 |
|
RU2658438C2 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
